Lantheus Holdings, Inc.
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound en…
Drug Manufacturers - Specialty & Generic
US, North Billerica [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | -16.43 | 4.84 | 5.80 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | -106.31 | -1.25 | -0.60 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 15.46 | 13.75 | 11.91 | |
| Cash | 0.27 | 10.45 | 10.42 | |
| Capex | 31.71 | -0.12 | -0.18 | |
| Free Cash Flow | 18.26 | 1.73 | 1.46 | |
| Revenue | 4.12 | 5.38 | 5.17 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | 4.80 | 0.68 | 0.65 | |
| Operating Margin | -30.14 | 0.27 | 0.39 | |
| ROA | 14.31 | 0.07 | 0.06 | |
| ROE | 9.40 | 0.14 | 0.13 | |
| ROIC | -28.96 | 0.05 | 0.07 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of LNTH is permitted for members.
5
Growth
The "Growth Entry" for the Focus of LNTH is permitted for members.
6
Leverage & Liquidity